ATE382051T1 - Prodrugs von pharmazeutika mit erhöhter bioverfügbarheit - Google Patents
Prodrugs von pharmazeutika mit erhöhter bioverfügbarheitInfo
- Publication number
- ATE382051T1 ATE382051T1 AT96919361T AT96919361T ATE382051T1 AT E382051 T1 ATE382051 T1 AT E382051T1 AT 96919361 T AT96919361 T AT 96919361T AT 96919361 T AT96919361 T AT 96919361T AT E382051 T1 ATE382051 T1 AT E382051T1
- Authority
- AT
- Austria
- Prior art keywords
- increased bioavailability
- prodrugs
- lipid prodrugs
- compositions
- pharmaceutical
- Prior art date
Links
- 229940002612 prodrug Drugs 0.000 title abstract 4
- 239000000651 prodrug Substances 0.000 title abstract 4
- 150000002632 lipids Chemical class 0.000 abstract 3
- 201000010099 disease Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 230000001093 anti-cancer Effects 0.000 abstract 1
- 230000003110 anti-inflammatory effect Effects 0.000 abstract 1
- 230000001028 anti-proliverative effect Effects 0.000 abstract 1
- 230000000840 anti-viral effect Effects 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 239000008177 pharmaceutical agent Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
- A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/06—Phosphorus compounds without P—C bonds
- C07F9/08—Esters of oxyacids of phosphorus
- C07F9/09—Esters of phosphoric acids
- C07F9/098—Esters of polyphosphoric acids or anhydrides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/06—Phosphorus compounds without P—C bonds
- C07F9/08—Esters of oxyacids of phosphorus
- C07F9/09—Esters of phosphoric acids
- C07F9/10—Phosphatides, e.g. lecithin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
- C07F9/40—Esters thereof
- C07F9/4003—Esters thereof the acid moiety containing a substituent or a structure which is considered as characteristic
- C07F9/4006—Esters of acyclic acids which can have further substituents on alkyl
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
- C07F9/40—Esters thereof
- C07F9/4003—Esters thereof the acid moiety containing a substituent or a structure which is considered as characteristic
- C07F9/4062—Esters of acids containing the structure -C(=X)-P(=X)(XR)2 or NC-P(=X)(XR)2, (X = O, S, Se)
- C07F9/4065—Esters of acids containing the structure -C(=X)-P(=X)(XR)2, (X = O, S, Se)
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Crystallography & Structural Chemistry (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Dispersion Chemistry (AREA)
- Epidemiology (AREA)
- Biophysics (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Virology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US08/487,081 US7517858B1 (en) | 1995-06-07 | 1995-06-07 | Prodrugs of pharmaceuticals with improved bioavailability |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE382051T1 true ATE382051T1 (de) | 2008-01-15 |
Family
ID=23934330
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT96919361T ATE382051T1 (de) | 1995-06-07 | 1996-06-07 | Prodrugs von pharmazeutika mit erhöhter bioverfügbarheit |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US7517858B1 (de) |
| EP (1) | EP0837630B1 (de) |
| JP (1) | JP4301571B2 (de) |
| AT (1) | ATE382051T1 (de) |
| AU (1) | AU711774B2 (de) |
| CA (1) | CA2223989C (de) |
| DE (1) | DE69637381T2 (de) |
| ES (1) | ES2299178T3 (de) |
| WO (1) | WO1996039831A1 (de) |
Families Citing this family (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE9603726D0 (sv) * | 1996-10-11 | 1996-10-11 | Astra Ab | Novel compounds |
| JP2002502831A (ja) * | 1998-02-03 | 2002-01-29 | イネックス ファーマシューティカルズ コーポレイション | 癌の治療に用いる血清に対して安定なプラスミド脂質粒子の全身供与 |
| US6410328B1 (en) * | 1998-02-03 | 2002-06-25 | Protiva Biotherapeutics Inc. | Sensitizing cells to compounds using lipid-mediated gene and compound delivery |
| IL131887A0 (en) * | 1999-09-14 | 2001-03-19 | Dpharm Ltd | Phospholipid prodrugs of anti-proliferative drugs |
| MXPA02006491A (es) * | 1999-12-29 | 2002-11-29 | Univ California | Tratamiento de infeccion por el virus de la inmunodeficiencia humana resistente a farmacos. |
| EP1460082A1 (de) * | 2003-03-19 | 2004-09-22 | Heidelberg Pharma Holding GmbH | Phospholipidester von clofarabin-derivate |
| ATE418966T1 (de) * | 2004-11-03 | 2009-01-15 | Liplasome Pharma As | Arzneimittelabgabesysteme auf lipidbasis mit unnatürlichen phospholipase-a2-abbaubaren lipid- derivaten und ihre therapeutische verwendung |
| EP1812012A4 (de) | 2004-11-15 | 2010-02-17 | Ceptyr Inc | Protein-tyrosin-phosphatasehemmer und verfahren zu ihrer verwendung |
| WO2006066074A2 (en) * | 2004-12-16 | 2006-06-22 | The Regents Of The University Of California | Lung-targeted drugs |
| WO2007107161A2 (en) * | 2006-03-23 | 2007-09-27 | Liplasome Pharma A/S | Lipid based drug delivery systems comprising phospholipase a2 degradable lipids that perform an intramolecular cyclization reaction upon hydrolysis |
| JP5320284B2 (ja) * | 2006-05-03 | 2013-10-23 | キメリクス，インコーポレーテッド | 抗ウイルス性または抗増殖性のホスホネート、ヌクレオシドホスホネートおよびヌクレオシドホスフェートの代謝安定性アルコキシアルキルエステル |
| ES2733353T3 (es) * | 2007-11-09 | 2019-11-28 | Basf As | Compuestos lípidos para uso en productos cosméticos, como suplemento alimenticio o como un medicamento |
| EP2070938A1 (de) * | 2007-12-13 | 2009-06-17 | Heidelberg Pharma AG | Clofarabin-Dietherphospholipid-Derivate |
| EP2234623A4 (de) * | 2007-12-27 | 2012-03-28 | Epiphany Biosciences | Antivirale verbindungen |
| US8586625B2 (en) * | 2008-01-16 | 2013-11-19 | Anwar Rayan | Derivatives of taxol and closely related compounds |
| EP2147910A1 (de) * | 2008-07-15 | 2010-01-27 | Pronova BioPharma Norge AS | Neue Lipid-Verbindungen |
| NZ618734A (en) | 2009-05-08 | 2015-01-30 | Pronova Biopharma Norge As | Polyunsaturated fatty acids for the treatment of diseases related to cardiovascular, metabolic and inflammatory disease areas |
| US8884027B2 (en) | 2010-10-22 | 2014-11-11 | University Of Rochester | Melampomagnolide B derivatives as antileukemic and cytotoxic agents |
| NZ610705A (en) | 2010-11-05 | 2014-10-31 | Pronova Biopharma Norge As | Methods of treatment using lipid compounds |
| US11351139B2 (en) | 2013-02-28 | 2022-06-07 | Basf As | Composition comprising a lipid compound, a triglyceride, and a surfactant, and methods of using the same |
| SI2970346T1 (sl) | 2013-03-15 | 2018-12-31 | The Regents Of The University Of California | Aciklični diestri nukleozid fosfonata |
| KR102466389B1 (ko) | 2014-03-14 | 2022-11-11 | 올텍 법인회사 | 셀레노유기 화합물의 조성물 및 이의 사용 방법 |
| EP3194411B1 (de) | 2014-09-15 | 2022-05-04 | The Regents of the University of California | Nukleotidanaloga |
| US9771385B2 (en) | 2014-11-26 | 2017-09-26 | Vascular Biogenics Ltd. | Oxidized lipids |
| CA2968790A1 (en) | 2014-11-26 | 2016-06-02 | Vascular Biogenics Ltd. | Oxidized lipids and treatment or prevention of fibrosis |
| EP3265102A4 (de) | 2015-03-06 | 2018-12-05 | ATEA Pharmaceuticals, Inc. | Beta-d-2'-deoxy-2'alpha-fluor-2'-beta-c-substituierte-2-modifizierte-n6-substituierte purinnukleotide zur hcv-behandlung |
| WO2016173923A1 (en) | 2015-04-28 | 2016-11-03 | Pronova Biopharma Norge As | Use of structurally enhanced fatty acids containing sulphur for preventing and/or treating non-alcoholic steatohepatitis |
| WO2017048252A1 (en) | 2015-09-15 | 2017-03-23 | Alltech, Inc. | Compositions of selenoorganic compounds and methods of use thereof |
| US10377782B2 (en) | 2015-09-15 | 2019-08-13 | The Regents Of The University Of California | Nucleotide analogs |
| LU100724B1 (en) | 2016-07-14 | 2018-07-31 | Atea Pharmaceuticals Inc | Beta-d-2'-deoxy-2'-alpha-fluoro-2'-beta-c-substituted-4'-fluoro-n6-substituted-6-amino-2-substituted purine nucleotides for the treatment of hepatitis c virus infection |
| PT3512863T (pt) | 2016-09-07 | 2022-03-09 | Atea Pharmaceuticals Inc | Nucleótidos de purina 2'-substituídos-n6-substituídos para tratamento de vírus de rna |
| CA3084728A1 (en) | 2017-12-06 | 2019-06-13 | Basf As | Fatty acid derivatives for treating non-alcoholic steatohepatitis |
| EP4017499A4 (de) | 2019-08-22 | 2024-01-10 | Emory University | Nukleosid-prodrugs und damit zusammenhängende verwendungen |
| WO2021173713A1 (en) | 2020-02-27 | 2021-09-02 | Atea Pharmaceuticals, Inc. | Highly active compounds against covid-19 |
| US10874687B1 (en) | 2020-02-27 | 2020-12-29 | Atea Pharmaceuticals, Inc. | Highly active compounds against COVID-19 |
| MX2023002233A (es) | 2020-08-24 | 2023-03-15 | Gilead Sciences Inc | Compuestos fosfolipidos y usos de estos. |
| TWI811812B (zh) | 2020-10-16 | 2023-08-11 | 美商基利科學股份有限公司 | 磷脂化合物及其用途 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE7607496L (sv) | 1976-07-01 | 1978-01-02 | Astra Laekemedel Ab | Sett for bekempning av virusinfektioner |
| CA1144937A (en) | 1977-12-22 | 1983-04-19 | Dke J.E. Helgstrand | Aromatic derivatives, pharmaceutical compositions and methods for combatting virus infections |
| EP0088046B1 (de) * | 1982-02-17 | 1987-12-09 | Ciba-Geigy Ag | Lipide in wässriger Phase |
| JPS61152694A (ja) * | 1984-12-27 | 1986-07-11 | Toyama Chem Co Ltd | 新規な５−フルオロ−２′−デオキシウリジン−５′−ホスフエ−ト誘導体およびその塩 |
| US5223263A (en) * | 1988-07-07 | 1993-06-29 | Vical, Inc. | Liponucleotide-containing liposomes |
| US5072032A (en) | 1989-06-21 | 1991-12-10 | Mckenna Charles E | Preparation and use of thiophosphonates and thio-analogues of phosphonoformic acid |
| US5411947A (en) * | 1989-06-28 | 1995-05-02 | Vestar, Inc. | Method of converting a drug to an orally available form by covalently bonding a lipid to the drug |
| US5194654A (en) | 1989-11-22 | 1993-03-16 | Vical, Inc. | Lipid derivatives of phosphonoacids for liposomal incorporation and method of use |
| US5463092A (en) * | 1989-11-22 | 1995-10-31 | Vestar, Inc. | Lipid derivatives of phosphonacids for liposomal incorporation and method of use |
| AU7872491A (en) | 1990-05-07 | 1991-11-27 | Vical, Inc. | Lipid prodrugs of salicylate and nonsteroidal anti-inflammatory drugs |
| DE4111105A1 (de) * | 1991-04-05 | 1992-10-08 | Max Planck Gesellschaft | Neue erucyl-, brassidyl- und nervonylderivate |
| DE4226279A1 (de) | 1992-08-08 | 1994-02-10 | Boehringer Mannheim Gmbh | Liponucleotide von Seco-Nucleosiden, deren Herstellung sowie deren Verwendung als antivirale Arzneimittel |
| US5512671A (en) | 1993-02-16 | 1996-04-30 | Wake Forest University | Ether lipid-nucleoside covalent conjugates |
| US5484911A (en) * | 1993-04-01 | 1996-01-16 | Health Research, Inc. | Nucleoside 5'-diphosphate conjugates of ether lipids |
-
1995
- 1995-06-07 US US08/487,081 patent/US7517858B1/en not_active Expired - Fee Related
-
1996
- 1996-06-07 AU AU61717/96A patent/AU711774B2/en not_active Expired
- 1996-06-07 CA CA2223989A patent/CA2223989C/en not_active Expired - Lifetime
- 1996-06-07 WO PCT/US1996/010054 patent/WO1996039831A1/en active IP Right Grant
- 1996-06-07 JP JP50218097A patent/JP4301571B2/ja not_active Expired - Fee Related
- 1996-06-07 AT AT96919361T patent/ATE382051T1/de not_active IP Right Cessation
- 1996-06-07 EP EP96919361A patent/EP0837630B1/de not_active Expired - Lifetime
- 1996-06-07 DE DE69637381T patent/DE69637381T2/de not_active Expired - Lifetime
- 1996-06-07 ES ES96919361T patent/ES2299178T3/es not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| EP0837630A4 (de) | 1998-11-25 |
| CA2223989A1 (en) | 1996-12-19 |
| AU6171796A (en) | 1996-12-30 |
| DE69637381T2 (de) | 2008-12-11 |
| CA2223989C (en) | 2010-11-23 |
| JPH11512078A (ja) | 1999-10-19 |
| US7517858B1 (en) | 2009-04-14 |
| ES2299178T3 (es) | 2008-05-16 |
| EP0837630A1 (de) | 1998-04-29 |
| AU711774B2 (en) | 1999-10-21 |
| WO1996039831A1 (en) | 1996-12-19 |
| EP0837630B1 (de) | 2007-12-26 |
| JP4301571B2 (ja) | 2009-07-22 |
| DE69637381D1 (de) | 2008-02-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE382051T1 (de) | Prodrugs von pharmazeutika mit erhöhter bioverfügbarheit | |
| ATE264671T1 (de) | Verfahren für die in-vivo-verabreichung von biologischen substanzen und hierfür verwendbare zusammensetzungen | |
| DE69604653D1 (de) | Taxol derivate, deren herstellung und diese enthaltende pharmazeutischen zusammenstellungen | |
| CY1113856T1 (el) | Διεργασια για την παραγωγη φαρμακοτεχνικων μορφων τριοξειδιου του αρσενικου | |
| ES2145774T3 (es) | Derivados de adenosina que tienen actividad agonista en a2. | |
| ES2186769T3 (es) | Complejos estables que comprenden lipidos para la administracion de farmacos y procedimientos para su produccion. | |
| UY26372A1 (es) | "imidazo-3-il-aminas bicíclicas procedimiento para su preparación y medicamentos que las contienen " | |
| FR2741066B1 (fr) | Nouveaux agents de transfection et leurs applications pharmaceutiques | |
| FI941452A (fi) | Yhdisteitä, jotka lisäävät muiden sytotoksisten aineiden kasvaimenvastaista aktiivisuutta | |
| MX9203602A (es) | Administracion iontoforetica mejorada de farmacos. | |
| FR2708606B1 (fr) | Dérivés du N-phénylalkylindol-2-one, leur préparation, les compositions pharmaceutiques en contenant. | |
| FR2764889B1 (fr) | Nouveaux derives du 2-(iminomethyl)amino-phenyle, leur preparation, leur application a titre de medicaments et les compositions pharmaceutiques les contenant | |
| MX9102701A (es) | Derivados de 2-acilamido de 3,4-dihidro-3-oxo-quinoxalina que tienen actividad farmaceutica. | |
| MX9601994A (es) | Profarmacos de derivados de paclitaxel. | |
| IT8323058A0 (it) | Derivati di 2,5-piperazindione biologicamente attivi, processi per la loro preparazione e composizioni farmaceutiche che licontengono. | |
| DE69610085D1 (de) | Taxol derivate,deren herstellung und diese enthaltende pharmazeutische zusammenstellungen | |
| FR2712289B1 (fr) | Nouveaux dérivés de taxicine, leur préparation et les compositions pharmaceutiques qui les contiennent. | |
| FR2705094B1 (fr) | Nouveaux dérivés du lupane, leur préparation et les compositions pharmaceutiques qui les contiennent. | |
| FR2705097B1 (fr) | Nouveaux dérivés du lupane, leur préparation et les compositions pharmaceutiques qui les contiennent. | |
| FR2691459B1 (fr) | Nouveaux derives de la phenothiazine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent. | |
| DE69626544T2 (de) | Arzneistoffe | |
| DK229984D0 (da) | 4-oxothiazolidin-2-yliden-acetamid-derivater | |
| ATE243683T1 (de) | Polyhydroxybutylpyrazinen, deren herstellung und diese enthaltende arzneimitteln | |
| PT1011329E (pt) | Paclitaxeis de 7-metiltio-oxometilo e 7-metiltiodioxometilo | |
| ES2084747T3 (es) | Polimeros en emulsion liberados de emulsionantes en preparados farmaceuticos con liberacion retardada de la sustancia activa, y su preparacion. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |